全部商品分类
用小程序，查商品更便捷
1μg (R: reducing condition, N: non-reducing condition).
IL-31 which produced by activated Th2-type T cells. IL-31 signals through a receptor composed of IL-31 receptor A and oncostatin M receptor. IL-31 activates STAT3 and possibly STAT1 and STAT5 through the IL-31 heterodimeric receptor composed of IL31RA and OSMR. IL-31 has also been identified as a major player in a number of chronic inflammatory diseases, including atopic dermatitis. Patients with atopic dermatitis, chronic spontaneous urticaria, allergic contact dermatitis, prurigo nodularis, primary cutaneous lymphoma and mastocytosis exhibit increased serum levels of IL-31 protein and elevated IL-31 mRNA in the skin.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.
1.J Allergy Clin Immunol. 2023 Jul 13;S0091-6749(23)00888-6. Online ahead of print.
2. Allergy. 2023 Jul 13. Online ahead of print.
3. Clin Exp Med. 2023 Jul 1. Online ahead of prin
参考图片
1μg (R: reducing condition, N: non-reducing condition).
Measured by its binding ability in a functional ELISA. When Recombinant Human IL-31 is immobilized 2.5µg/mL (100µL/well), Recombinant Human OSMR/IL-31RB His Tag binds with an EC50 of 1.3-1.6μg/ml.
Measured by its binding ability in a functional ELISA. When Recombinant Human IL-31 is immobilized 2.5µg/mL (100µL/well), Recombinant Mouse IL-31RA Fc chimera binds with an EC50 of 0.07-0.1μg/ml.
Measured by its ability to induce STAT3 activation in U‑87 MG human glioblastoma/astrocytoma cells. The EC50 for this effect is less than 30ng/ml can effectively induce STAT3 activation.